- Home
- KOS vs ABUS Comparison
KOS vs ABUS Comparison
Compare KOS & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KOS
- ABUS
- Stock Information
- Founded
- KOS 2003
- ABUS 2005
- Country
- KOS United States
- ABUS United States
- Employees
- KOS N/A
- ABUS N/A
- Industry
- KOS Oil & Gas Production
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- KOS Energy
- ABUS Health Care
- Exchange
- KOS Nasdaq
- ABUS Nasdaq
- Market Cap
- KOS 870.4M
- ABUS 711.2M
- IPO Year
- KOS 2011
- ABUS N/A
- Fundamental
- Price
- KOS $1.80
- ABUS $4.43
- Analyst Decision
- KOS Buy
- ABUS Strong Buy
- Analyst Count
- KOS 6
- ABUS 2
- Target Price
- KOS $4.32
- ABUS $5.00
- AVG Volume (30 Days)
- KOS 7.8M
- ABUS 1.6M
- Earning Date
- KOS 11-03-2025
- ABUS 11-05-2025
- Dividend Yield
- KOS N/A
- ABUS N/A
- EPS Growth
- KOS N/A
- ABUS N/A
- EPS
- KOS N/A
- ABUS N/A
- Revenue
- KOS $1,488,836,000.00
- ABUS $15,416,000.00
- Revenue This Year
- KOS N/A
- ABUS $138.02
- Revenue Next Year
- KOS $13.62
- ABUS N/A
- P/E Ratio
- KOS N/A
- ABUS N/A
- Revenue Growth
- KOS N/A
- ABUS 53.23
- 52 Week Low
- KOS $1.39
- ABUS $2.71
- 52 Week High
- KOS $4.69
- ABUS $5.10
- Technical
- Relative Strength Index (RSI)
- KOS 51.80
- ABUS 63.83
- Support Level
- KOS $1.65
- ABUS $4.37
- Resistance Level
- KOS $1.81
- ABUS $5.10
- Average True Range (ATR)
- KOS 0.10
- ABUS 0.26
- MACD
- KOS 0.02
- ABUS 0.03
- Stochastic Oscillator
- KOS 76.00
- ABUS 55.33
About KOS Kosmos Energy Ltd. (DE)
Kosmos Energy Ltd is a deepwater exploration and production company focused on meeting the world's growing demand for energy. It has diversified oil and gas production from assets offshore Ghana, Equatorial Guinea, Mauritania, Senegal and the Gulf of America. The Company had operations in four geographic reporting segments: Ghana, Equatorial Guinea, Mauritania/Senegal and the Gulf of America. The majority of revenue is derived from the Ghana segment.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.